EIF4A3-IN-1

CAT: 0804-HY-101513-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-101513-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
EIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities[1][2][3].
CAS Number
[2095486-67-0]
UNSPSC
12352005
Target
Eukaryotic Initiation Factor (eIF)
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/eif4a3-in-1.html
Purity
99.96
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
ClC(C=C1)=CC=C1[C@@H]2N(C(C3=CC=C(Br)C=C3)=O)CCN(C(C4=C(C)N(C5=CC=CC(C#N)=C5)N=C4)=O)C2
Molecular Formula
C29H23BrClN5O2
Molecular Weight
588.88
References & Citations
[1]Ito M, et al. Discovery of Novel 1,4-Diacylpiperazines as Selective and Cell-Active eIF4A3 Inhibitors. J Med Chem. 2017 Apr 27;60 (8) :3335-3351.|[2]López-Cánovas JL, et al. Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing. Clin Transl Med. 2022 Nov;12 (11) :e1102.|[3]Hsieh MC, et al. Phosphorylated Upstream Frameshift 1-dependent Nonsense-mediated μ-Opioid Receptor mRNA Decay in the Spinal Cord Contributes to the Development of Neuropathic Allodynia-like Behavior in Rats. Anesthesiology. 2023 Jun 1;138 (6) :634-655.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EIF4

Popular Products